BioCryst Pharmaceuticals, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $218.3M | $156.4M | $406.6M | $159.4M | $163.4M | $145.5M | $131.5M | $117.1M |
| Cost of Revenue | $3.8M | $5.4M | $9.5M | $2.2M | $2.8M | $4.6M | $6.1M | $3.2M |
| Gross Profit | $214.4M | $151.0M | $397.0M | $157.2M | $160.6M | $141.0M | $125.4M | $113.9M |
| Gross Margin | 98.2% | 96.6% | 97.7% | 98.6% | 98.3% | 96.9% | 95.4% | 97.3% |
| Operating Expenses | ||||||||
| Research & Development | $52.0M | $60.3M | $40.9M | $44.6M | $43.4M | $37.3M | $49.4M | $41.1M |
| SG&A Expense | $64.0M | $94.6M | $95.8M | $83.0M | $87.4M | $82.5M | $80.5M | $65.1M |
| Operating Income | $98.5M | $-701.6M | $260.4M | $29.6M | $29.8M | $21.2M | $-4.5M | $7.7M |
| Operating Margin | 45.1% | -448.6% | 64.0% | 18.6% | 18.2% | 14.6% | -3.4% | 6.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $79.5M | $-720.8M | $248.0M | $12.1M | $6.5M | $758.0K | $-26.0M | $-13.4M |
| Income Tax Expense | $1.1M | $1.0M | $2.2M | $-769.0K | $1.4M | $726.0K | $804.0K | $586.0K |
| Net Income | $78.4M | $-721.8M | $245.8M | $12.9M | $5.1M | $32.0K | $-26.8M | $-14.0M |
| Net Margin | 35.9% | -461.5% | 60.5% | 8.1% | 3.1% | 0.0% | -20.4% | -12.0% |
| EPS (Basic) | $0.31 | $-2.98 | $1.18 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 |
| EPS (Diluted) | $0.30 | $-2.98 | $1.13 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 |
| Shares Outstanding (Basic) | 254.5M | 242.3M | 209.9M | 210.2M | 209.5M | 208.9M | 206.7M | 206.9M |
| Shares Outstanding (Diluted) | 265.2M | 242.3M | 218.6M | 219.9M | 219.9M | 215.3M | 206.7M | 206.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |